Loading...
Loading...
SHPH| Name | Value |
|---|---|
| Revenues | 0.0K |
| Cost of Revenue | 1.5K |
| Gross Profit | -1.5K |
| Operating Expense | 1,465.6K |
| Operating I/L | -1,465.6K |
| Other Income/Expense | -718.7K |
| Interest Income | 19.3K |
| Pretax | -2,184.4K |
| Income Tax Expense | 731.9K |
| Net Income/Loss | -2,184.4K |
Shuttle Pharmaceuticals Holdings, Inc. and its subsidiary, Shuttle Pharmaceuticals, Inc., specialize in developing and commercializing drugs that enhance the effectiveness of radiation therapy for cancer treatment. Their clinical stage products include Ropidoxuridine, an oral medication for brain tumors and soft tissue sarcomas, and Doranidazole, an injectable radiation sensitizer for pancreatic, lung, and liver cancers.
